Friendly bacteria cream could soothe childhood eczema
NCT ID NCT07701447
First seen Jul 14, 2026 · Last updated Jul 16, 2026 · Updated 2 times
Summary
This study tests whether a probiotic ointment (containing live, friendly bacteria) can improve eczema in children aged 6 months to 15 years. The ointment is compared to a basic lotion over 28 days. Researchers measure skin redness, itching, and skin barrier function to see if the probiotic cream offers extra relief.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- a probiotic ointment
- What this could lead to
- If it works, this could offer a gentle, bacteria-based cream to help manage eczema in children.
- What could go wrong
- This is a small, early-stage study. The ointment may not improve symptoms more than a basic lotion, and individual results may vary.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 92 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Aug 2026
An estimate. Start dates often move.
- Expected to finish
-
Nov 2028
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
6 months to 15 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria Male and female pediatric patients aged 0.5 years to 15 years with Atopic Dermatitis. SCORAD Index at D0 = 15 to 50, inclusive. In goodgeneral health as reported by the parent(s)/legal representative(s). Available for the full duration of the study and willing to comply with procedures. Subjects whose parents or legal representative are willing to sign the informed consent. Exclusion Criteria Use of phototherapy for atopic dermatitis. Use of systemic corticosteroids within 2 weeks prior to the study. Use of Immunosuppressive or cytostatic drugs within 1 months prior to the study. Use of antibiotics (topical and systemic) within 15 days prior to the start of the study. Subjects who are treated with vitamin A-derived compounds or other topical medications for acne in the experimental area during the 30 days prior to the start of the study. History of sensitivity to the study products, or its components. History or evidence of allergies requiring acute or chronic treatment (except seasonal allergic rhinitis). Subjects with active infection in atopic dermatitis areas requiring antibiotics, antifungals, or antiviral agents within 7 days before baseline participation in any study that would interfere with the current study. Fever (temperature\> 37.5 °C axillary or equivalent) during 48 hours prior the start of the study. Pathologies associated with immunodeficiency or cancer processes. Any concurrent dermatologic or medical conditions that may interfere with the investigators ability to assess the subject's response to the study drug or require the continued use of topical corticosteroids. Subjects who have received the schedule MMR vaccination during the study period or have received the last dose within three weeks prior the start of the study. Subjects who participates in any study that would interfere with the current study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Atopic dermatitis are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an eczema drug reshape the Skin's microbial community?
- Can a pill tame severe eczema? a new trial puts QX-4533 to the test
- Can a probiotic soothe Children's eczema?
- Could junk food fuel eczema in kids?
- Can a daily pill calm severe eczema from the inside?
- Can we predict the path of chronic skin disease?